AU2020401837A1 - Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction - Google Patents

Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction Download PDF

Info

Publication number
AU2020401837A1
AU2020401837A1 AU2020401837A AU2020401837A AU2020401837A1 AU 2020401837 A1 AU2020401837 A1 AU 2020401837A1 AU 2020401837 A AU2020401837 A AU 2020401837A AU 2020401837 A AU2020401837 A AU 2020401837A AU 2020401837 A1 AU2020401837 A1 AU 2020401837A1
Authority
AU
Australia
Prior art keywords
individual
antibody
amount
diabetic
diastolic dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020401837A
Other languages
English (en)
Inventor
Juliane CZECZOR
Liam Hall
Sean Mcgee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambetex Pty Ltd
Original Assignee
Ambetex Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904682A external-priority patent/AU2019904682A0/en
Application filed by Ambetex Pty Ltd filed Critical Ambetex Pty Ltd
Publication of AU2020401837A1 publication Critical patent/AU2020401837A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2020401837A 2019-12-11 2020-11-20 Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction Pending AU2020401837A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904682A AU2019904682A0 (en) 2019-12-11 Compositions and methods for prevention and treatment of cardiovascular disease.
AU2019904682 2019-12-11
PCT/AU2020/051254 WO2021113899A1 (en) 2019-12-11 2020-11-20 Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction

Publications (1)

Publication Number Publication Date
AU2020401837A1 true AU2020401837A1 (en) 2022-07-21

Family

ID=76328764

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020401837A Pending AU2020401837A1 (en) 2019-12-11 2020-11-20 Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction

Country Status (5)

Country Link
US (1) US20230027014A1 (https=)
EP (1) EP4073113A4 (https=)
JP (1) JP2023506450A (https=)
AU (1) AU2020401837A1 (https=)
WO (1) WO2021113899A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
WO2025165940A1 (en) * 2024-02-01 2025-08-07 Calviri, Inc. Methods and compositions for reducing non-tumor disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200501524A1 (ru) * 2003-03-28 2006-06-30 Сентокор, Инк. Антитела против амилоида, композиции, способы и применения
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
US20100028351A1 (en) * 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
DK2182983T3 (da) * 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
US20100074901A1 (en) * 2007-10-15 2010-03-25 Marc Hubert Mercken Human anti-amyloid antibodies, compositions, methods and uses
US20110178024A1 (en) * 2008-09-29 2011-07-21 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US20130084245A1 (en) * 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
AU2020401838A1 (en) * 2019-12-11 2022-07-21 Ambetex Pty Ltd Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction

Also Published As

Publication number Publication date
US20230027014A1 (en) 2023-01-26
EP4073113A4 (en) 2024-02-14
WO2021113899A1 (en) 2021-06-17
JP2023506450A (ja) 2023-02-16
EP4073113A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
JP2019504064A (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用方法
JP6312748B2 (ja) 脂質動員特性を有する糖タンパク質およびその治療的使用
EP3083683B1 (en) Compositions and methods for treating fatty tissue buildup
US10858449B1 (en) Methods and compositions for treating osteoarthritis
WO2022271867A1 (en) A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
BR112020002155A2 (pt) métodos e composições para o tratamento de doenças de deposição de amiloide
CN114630681A (zh) 包含actrii受体拮抗剂的肝疾病或障碍的治疗
JP2022023195A (ja) 最適な体重及び血糖を維持するための新規ポリペプチドホルモンの同定
US11161898B2 (en) Anti-amyloid-beta antibodies
US20200353079A1 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
AU2020401837A1 (en) Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction
CN112839672A (zh) 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法
US20260001949A1 (en) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
US20230028659A1 (en) Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
KR20230140362A (ko) 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물
US20230029372A1 (en) Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
CN106883295B (zh) 人内皮素a型受体免疫原性肽段及其载体疫苗
WO2016004208A1 (en) Cthrc1 receptor and methods of use thereof
HK40040990A (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
WO2015165971A1 (en) Treatment and prevention of alzheimer's disease (ad)
EP4072557A1 (en) Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
HK40053201B (en) Compositions and methods for treating fatty tissue buildup
HK40003330A (en) Asprosin, a fast-induced glucogenic protein hormone
HK1225640B (zh) 治疗脂肪组织积聚的组合物和方法